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Abstract
Background: The treatment of metastatic breast cancer (MBC) remains a great clinical challenge as drug resistance
frequently develops. Alternative agents that can overcome drug resistance would offer new therapeutic options.
The primary aim of this phase II study was to evaluate the efficacy and safety of utidelone as a monotherapy or
in combination with capecitabine in metastatic breast cancer patients previously treated with and resistant to
anthracyclines and taxanes.
Methods: In two open-label, noncomparative clinical studies, patients with metastatic breast cancer who previously
received anthracycline- and/or taxane-containing regimens were given (1) 25 to 35 mg/m2/day intravenously
infused utidelone, once daily for 5 days, in combination with 14 days of 2000 mg/m2 capecitabine, divided in two
equal daily oral doses or (2) 40 mg/m2/day intravenously infused utidelone, once daily for 5 days. These regimens
were administered per each 21-day treatment cycle, and the maximum of treatment cycles allowed per protocol is
6. Objective response rate (ORR), progression-free survival (PFS), and tolerability were evaluated.
Results: In the combination study, 33 patients completed a median of 6 cycles of therapy, which was the highest
cycles a trial patient could receive under the criteria of the study protocol. Efficacy was evaluated (n = 32) with an
ORR of 42.4 % (FAS, 95 % CI, 26.6, 60.9) and a median PFS of 7.9 (FAS, 95 % CI, 6.1, 9.8) months. The monotherapy
study (n = 63) resulted in an ORR of 28.57 % (FAS, 95 % CI, 18.4, 40.6) and a median PFS of 5.4 (FAS, 95 % CI, 2.9,
9.8) months. In both studies, common toxicities associated with utidelone administration included peripheral
neuropathy, fatigue, myalgia, and arthralgia, but the toxicities were limited and manageable. Notably, very mild
myelosuppression, low liver and renal toxicities, and very limited gastrointestinal toxic effect were observed, in
contrast to other agents in the same class.
Conclusions: Utidelone showed promising efficacy, tolerability, and advantageous safety profiles in the treatment
of patients with advanced anthracycline/taxane-refractory metastatic breast cancer and may offer new treatment
options to overcome drug resistance.
Trial registration: CHiCTR-TRC-13004205, registered on August 15, 2013.
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Background
Epothilones are a class of naturally existing molecules
produced by the myxobacterium Sorangium cellulosum.
Bollag et al. [1] first identified the potential antineoplastic
activity of epothilones, with a similar mechanism of action
to taxanes. Specifically, epothilone binds to the β-subunit
of the αβ-tubulin heterodimer, induces the formation of
microtubule bundles, stabilizes the microtubule assembly,
and prevents their depolymerization. This inhibits the for-
mation of mitotic spindles and disrupts cell mitosis and
other cellular growth and repair mechanisms. As a result,
epothilone suppresses tumor cell growth, causing cytotox-
icity and apoptosis.
Despite the similar mechanism of action, the molecu-
lar structure of epothilones differs from that of taxanes.
Thus, tumor cells resistant to taxanes remain sensitive
to epothilones’ cytotoxic effects [2]. As resistance to tax-
anes becomes an increasing challenge in their clinical
use, alternative agents that can overcome tumor drug re-
sistance would offer new therapeutic options for patients
whose tumors recur or progress after taxane treatment.
In preclinical research, epothilone analogs have demon-
strated more potent cytotoxic activity than taxanes and
activity against tumor cell lines with multidrug resistance
[3]. Ixabepilone (Ixempra®), a semi-synthetic epothilone
analog, is the only drug in this class that has been ap-
proved by the United States Food and Drug Administra-
tion (FDA) as monotherapy to treat metastatic or locally
advanced breast cancer patients after failure of an anthra-
cycline, a taxane, and a capecitabine treatment [4]. The
combination of ixabepilone plus capecitabine is indicated
for the treatment of metastatic or locally advanced breast
cancer in patients after failure of an anthracycline and a
taxane [5].
Utidelone (UTD1) is an analog of epothilone generated
by genetically manipulating the polyketide biosynthetic
gene cluster in S. cellulosum [6]. This agent was developed
and manufactured by Biostar Technologies, Ltd., Beijing,
China. Previously, we had conducted a phase I and a phase
Ib study [6] (and unpublished data); limited, short-term
toxicities, and encouraging preliminary efficacy results
were obtained. Especially in the phase Ib study, we tested
30, 35, and 40 mg/m2 three different utidelone doses,
given intravenously once daily for 5 days per 21-day cycle,
instead of single dosing every 21 days as in the phase I trial
[6]. These previous studies showed that the continuous 5-
day dosing regimen gave better efficacy (unpublished data)
than the single dosing regimen [6]. The DLT of the 5-day
dosing regimen of utidelone was peripheral neuropathy,
and the MTD was 40 mg/m2/day (unpublished data).
Based on these earlier studies, this phase II multicenter
clinical trial was designed and initiated to evaluate the effi-
cacy and safety of utidelone in heavily pretreated patients
of metastatic breast cancer.
Methods
Patients
The patients were 18- to 70-year-old female patients
who were histologically or cytologically diagnosed with
advanced metastatic breast cancer and had received no
more than three regimens of chemotherapies (the adju-
vant therapy did not count as one regimen) in the past
or experienced recurrence. The previous chemotherapy
regimens must have included an anthracycline and/or a
taxane (including neoadjuvant and adjuvant therapies),
but no more than three chemotherapy regimens were
given in the metastatic setting. Additional inclusion cri-
teria included an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 to 2, life expectancy of
at least 3 months, at least one target site that could be
evaluated via imaging techniques, and nervous system
disorders lower than grade 2 on the National Cancer In-
stitute (NCI) Common Toxicity Criteria (CTC) version
4.03. Informed consent was obtained from each patient
before initiating study procedures, and studies were
performed in accordance with the appropriate locally
governing institutional review board committee, formally
designated to approve, monitor, and review biomedical re-
search involving human study subjects.
Study design and treatment
This research consisted of two open-label, noncomparative,
phase II clinical studies of utidelone. The studies included a
utidelone plus capecitabine combination study and a utide-
lone alone monotherapy study.
The combination therapy study was conducted in two
stages. First, a dose escalation study was conducted at
one clinical study site (n = 3–5 patients per dose) with
intravenously infused utidelone administered once daily
for 5 days, in combination with 1000 mg/m2 twice daily
oral capecitabine (Hoffmann-La Roche AG, Basel,
Switzerland) for 14 days in each 21-day treatment cycle.
Three doses (25, 30, 35 mg/m2/day) were escalated;
three to five patients per dose were treated. Based on
the safety and efficacy results obtained from the three
dose groups, the second stage of the study was ex-
panded to three clinical study sites with the MTD dose
(30 mg/m2/day) of utidelone, chosen for all subsequent
study subjects to be administered with capecitabine.
Eligible patients were continually enrolled into the study
until the total number of study subjects reached the
planned sample size of 21 patients. This sample size was
determined according to a superiority design, α = 0.10,
β = 0.80, using a phase III trial result of ixabepilone as a
reference, which had an objective response rate (ORR)
of 34 % for ixabepilone plus capecitabine, and an ORR
of 14 % for capecitabine alone.
In the monotherapy study, eligible patients were given
utidelone 40 mg/m2 daily for 5 days in each 21-day
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treatment cycle. In this trial, multicenter two-stage de-
sign was used with an ORR of 15 %, a null response rate
of 5 %, a type one error of 0.10, and a type two error of
0.10. As such, continuation to the second stage required
at least 1 patient out of the first 15 to demonstrate par-
tial response (PR) or complete response (CR). Eligible
patients were continually enrolled into the second stage
until the total number of study subjects reached the
planned sample size of 60 patients. The study strategy
and design was illustrated in Fig. 1.
Efficacy and tolerability assessments
The primary endpoint measured in both studies was ORR
determined according to Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.1. The secondary end
points included progression-free survival (PFS) and safety.
Safety was monitored by investigator and laboratory tests.
Study subjects were evaluated for tumor response every
two treatment cycles. Those with status of stable disease
(SD), PR, or CR were eligible to continue the study treat-
ment for up to six treatment cycles or until discontinuation
due to disease progression or intolerable toxicity. After the
end of treatment, post-monitoring of study subjects with
SD or better efficacy was conducted every 3 months until
disease progression or death. Study subjects who discontin-
ued study treatment due to reasons other than progression
were followed every 3 months thereafter until disease
progression or death.
Routine hematologic laboratory tests were performed
once weekly, between day 3 and day 5, until the completion
or discontinuation of study treatment. Routine biochemis-
try laboratory tests were performed once every cycle be-
tween day 3 and day 5 in study week 3. In addition, ECG,
vital signs, and physical examination were performed at
regular intervals during the study for abnormalities and sig-
nificant changes from baseline. All assessments and tests
were performed at the baseline and end-of-treatment visits.
Additional and more frequent tests could be ordered at the
investigator’s discretion.
Statistical analysis
The efficacy and safety variables were summarized using
descriptive statistics, as no comparator was used in this
research. Survival curves were estimated using the
Kaplan-Meier method. For the efficacy variables (i.e.,
ORR, PFS), 95 % confidence intervals were calculated
using the Clopper Pearson method.
Results
Study subjects and treatment cycle completion
The demographic information of patients for both
monotherapy and combination therapy is summarized
in Table 1. All study subjects were Chinese women with
stage IV breast cancer whose ages ranged from 28 to
71 years (one patient is 71, over the age 70 inclusion
criteria requirement, but a study deviation was permit-
ted). The median age was 50.3 years in the combination
therapy study and 50.9 years in the monotherapy study.
Most study subjects had metastases to the liver and/or





















Fig. 1 Study strategy and design. Patients previously received three or fewer chemotherapeutic regimens (not including adjuvant therapy) with
MBC were enrolled. Both combination therapy and monotherapy were carried out in two stages. In the first stage of combination therapy, three
doses of utidelone (30, 35, and 40 mg/m2/day) plus capecitabine (2000 mg/m2/day) were tested, with each dose group recruiting 3–5 patients of
total 12 patients. Based on the efficacy and toxic effects of the combined agents, 30 mg/m2/day dosing regimen was selected, which demonstrated
better safety profile with promising efficacy, as the dose for the second stage that recruited 21 patients. For the monotherapy, compare two different
dosing regimens in the first stage: (1) 170 mg/m2 iv, once every 21 days; (2) 40 mg/m2 iv, once daily for 5 days every 21 days. Patients were randomized
into the two different regimens, and 15 patients for each group were enrolled. Based on the efficacy and safety of the first stage, 40 mg/m2/day dosing
regimen was chosen for the second stage to continue recruitment until target patient number reached 55. Efficacy evaluation was carried out once
every 2 cycles, and the primary endpoint ORR was assessed
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received both taxanes and anthracyclines, and over
30 % had also received capecitabine.
The study strategy and design was illustrated by
Fig. 1.The first stage of combination therapy was carried
out to determine an optimal dose regimen; 25, 30, or
35 mg/m2/day utidelone plus 2000 mg/m2/day capecita-
bine was conducted in one study site. Three patients
were administered the 25-mg/m2/day dose, four were
administered the 30-mg/m2/day dose, and five were ad-
ministered the 35-mg/m2/day dose. The DLT of the
combination was peripheral neuropathy and was ob-
served at 35 mg/m2/day dose, and the MTD for utide-
lone was 30 mg/m2/day. Based on the results from the
first stage of the combination therapy, the MTD dose
30 mg/m2/day with better efficacy and safety profile
was chosen for the later enrolled patients, and the
study was expanded to three study sites until the total
number of study subjects reached the planned sample
size of 21 patients for the 30-mg/m2/day dose group. A
total of 33 patients with late-stage metastatic breast
cancer were enrolled from July 2012 to April 2013.
Eighteen of the 33 study subjects completed the max-
imal six treatment cycles specified in the protocol. Two
study subjects requested and were allowed for one and
two additional cycles of compassionate treatment after
completing 6 cycles. The median number of treatment
cycles completed was six, which was the highest cycles
a trial patient could receive under the criteria of the
study protocol.
The monotherapy study with 40 mg/m2/day utidelone
was conducted at eight enrollment sites starting in August
2012. The last patient was enrolled in June 2014. A total
of 70 study subjects with late-stage metastatic breast can-
cer were enrolled. Twenty of the 70 study subjects com-
pleted the maximal 6 cycles of treatment. Three study
subjects requested and were allowed one to two additional
treatment cycles of compassionate treatment after com-
pleting 6 cycles. The median number of treatment cycles
completed for the monotherapy study was 3.5; 12.9 % re-
quired reduction of utidelone in the monotherapy study.
Table 1 Study subject demographics
Demographic characteristic Combination therapy study: utidelone (30 mg/m2)
and capecitabine (2000 mg/m2) n = 33
Monotherapy study: utidelone
(40 mg/m2) n = 70
Age (year) Median 50 51
Range 28–66 31–71
Sex, n (%) Female 33 (100) 70 (100)
ECOG PS, n (%) 0 19 (57.6) 9 (12.9)
1 14 (42.4) 60 (85.7)
2 0 (0.0) 1 (1.4)
Clinical stage, n (%) IV 33 (100) 70 (100)
Metastasis site, n (%) ≤2 20 (60.6) 47 (67.1)
>2 13 (39.4) 23 (32.9)
Number of target lesions, n (%) 1 18 (54.5) 39 (55.7)
2 10 (30.3) 18 (25.7)
>2 5 (15.2) 13 (18.6)
Past chemotherapy courses, n (%) 1 6 (18.2) 10 (14.3)a
2 12 (36.4) 20 (28.6)
3 or more 15 (45.5) 40 (57.1)
Past treatment regimens
containing, n (%)
Anthracyclines 33 (100) 67 (95.7)
Taxanes 30 (90.9) 67 (95.7)
Taxanes + anthracyclines 27 (81.8) 64 (91.4)
Capecitabine 13 (39.4) 34 (48.6)
Taxanes + anthracyclines +
capecitabine
11 (33.3) 33 (47.1)
Concurrent diseases or
complications, n (%)
No 30 (90.0) 54(77.1)
Yes 3 (9.1) 16(22.9)
Primary tumor excised, n (%) Yes 32(97.0) 68(97.1)
Received radiation therapy, n (%) Yes 18(57.6) 48 (68.6)
ECOG PS Eastern Cooperative Oncology Group performance status
aNeoadjuvant and/or adjuvant chemotherapy
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The number of study subjects completed treatment cycles
is summarized in Table 2.
Efficacy
In the combination therapy study, one study subject in
the 30-mg/m2 dose group discontinued the study be-
cause of an AE (considered unlikely to be related to the
study drug) before completing the first treatment cycle
and was deemed not evaluable. Therefore, 32 combin-
ation therapy study subjects were evaluable for efficacy.
The ORR was 42.4 % (FAS), which included one study
subject who had CR and 13 study subjects who had PR
(Table 3), 95 % CI (26.6 %, 60.9 %). Twenty-two (66.7 %,
FAS) study subjects achieved response (CR or PR) or
maintained stable disease for 6 months or longer. Of the
14 study subjects with CR or PR, three had received
prior chemotherapies containing an anthracycline, a tax-
ane, and capecitabine. Of the 15 study subjects with SD,
six had received prior chemotherapies containing all
three types of agents. By the study end date (Jan. 31,
2014) in terms of PFS, 26 (78.8 %) patients experienced
disease progression. The median PFS (Fig. 2) was
7.9 months (FAS, 95 % CI = 6.1, 9.8), and the median
duration of response was 7.8 months. Eighteen patients
(54.5 %) had died by Jan. 23, 2016.
In the monotherapy study, 63 (90 %) of the 70 enrolled
study subjects completed at least 2 cycles of treatment
and were therefore evaluable for efficacy. Of the seven
study subjects not evaluable for efficacy, two discontin-
ued during the first cycle due to SAEs and two termi-
nated due to AEs after completing the first cycle, one
left the study due to lung metastasis and severe cough
and two others withdrew from the study for other rea-
sons. Of the 63 study subjects evaluated, 20 completed
6 cycles of utidelone treatment, 26 discontinued before
completing 6 cycles because of PD, and 17 did not
complete 6 cycles because of AE or other reasons. By
the end of the study, 1 study subject with CR, 19 with
PR (including two with unconfirmed PR), and 25 with
SD (Table 3) were observed. The ORR was 28.57 %
(95 % CI 18.4, 40.6). The median duration of response
was 7.4 months. Twenty-nine study subjects achieved
clinical benefits, defined as maintaining stable disease or
response (CR or PR) for at least 6 months. The median
time to response was 6 weeks. By the study end date
(Dec. 31, 2014), 45 (64.3 %) of the 70 enrolled patients
had disease progression, including 6 who had died without
observing PD. The median PFS (Fig. 1) for FAS was
5.4 months (95%CI, 2.9, 9.8). Thirty-three patients (47.1 %)
had died by Jan. 23, 2016.
Tolerability
The most common AEs reported in the combination
therapy and monotherapy studies are summarized in
Table 4 using NCI CTCAE version 3.0 grade criteria. In
the combination therapy, 33 patients were evaluable for
safety. No SAEs occurred or deaths resulted that were
attributed to the study treatment. The major AE associ-
ated with uitdelone was peripheral neuropathy (PN), pri-
marily classified as sensory. Grade 3 PN was reported
for 45.5 % of the combination therapy study subjects
and was managed with dose reduction, increasing dosing
interval, treatment interruption, or symptomic manage-
ment by adjunctive treatments. The majority of the study
subjects continued dosing after recovering to grade 1 or
better within 2 weeks. Other toxicities were as expected
for this combination therapy, including hand-foot syn-
drome resulted from capecitabine, nausea, vomiting,
myalgia and arthralgia, fatigue, and alopecia. Most of
the AEs were grade 1 or 2 and were considered man-
ageable and reversible.
In the monotherapy study, 70 patients were evaluated
for safety. The major AE related to utidelone was PN
(78.6 % for all grades), most of which were grades 1 and
2 with six study subjects experiencing grade 3 PN
(8.6 %). Of the 29 study subjects experiencing grade 2 or
3 PN, the median time to recovery was 18 days. All
study subjects with severe PN (grade 3) experienced
symptom resolution to grade 1 or less following cessa-
tion of utidelone administration. Other frequent AEs in-
cluded short-term myalgia, arthralgia, nausea, vomiting,
and loss of appetite. All AEs were considered manage-
able. Neutropenia occurred in 19 (27.1 %) of the 70
study subjects in the monotherapy study. Five study sub-
jects (7.1 %) in the monotherapy study experienced
grade 3 neutropenia; however, two were considered ab-
normal at study onset, prior to administration of the first
treatment.
Table 2 Study subject treatment cycles completed
Combination therapy study:








30 mg/m2/day for 5 days
per cycle











aCompassionate treatment for additional treatment beyond 6 cycles were
allowed for some patients for their benefits
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Two SAEs occurred during the monotherapy study,
one study subject experienced a grade 3 neurological
toxicity during cycle 1, presenting with headache and
peripheral neuropathy that led to hospitalization. Symp-
toms were resolved and the study subject was recovered
3 weeks after discontinuation of utidelone treatment.
Another study subject experienced myocardial ischemia
after cycle 1, which resulted in prolonged hospitalization.
Both SAEs were considered probably related to utidelone
administration.
Laboratory tests, vital signs, and physical examination
In general, very limited and mild myelosuppression tox-
icity was observed in both monotherapy and combination
studies, indicating a very unique and advantageous feature
of utidelone compared with ixabepilone and taxanes. In
addition, abnormal liver and renal functions were not
frequently found, suggesting utidelone treatment, under
conditions of these studies, was unlikely to result in
significant adverse liver and renal function effects.
Moreover, diarrhea was not observed frequently, impli-
cating that the gastrointestinal toxic effect of utidelone
is quite mild. Other observed toxicities were consistent
with the common adverse events of chemotherapy
agents. Two study subjects had abnormal blood glucose
levels, which were deemed unlikely to be related to the
study treatment. Clinically significant abnormal levels
of serum creatinine and blood urea nitrogen were not
observed. Abnormal clinical laboratory test measurements
reported for any study subjects during the course of treat-
ment were not considered severe enough to require dose
adjustment or treatment interruption. Clinically significant
Table 3 Study subject end of treatment objective response rates
Utidelone starting dose, mg/m2 Best response,a n ORR,b %
CR PR SD PD NA Total ORR 95 % CIc
Combination therapy: utidelone (30 mg/m2) and capecitabine (2000 mg/m2) n = 33
25 0 2 1 0 0 3 66.7 9.4, 99.2
30 1 11 10 2 1 25 48.0 27.8, 68.7
35 0 0 4 1 0 5 0 –
Total 1 13 15 3 0 33 42.4 26.6, 60.9
Monotherapy: utidelone (40 mg/m2) n = 70
40 1 19d 25 18 7 70 28.57 18.40, 40.62
CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, CI confidence interval
aAssessed according to RECIST1.1
bORR = (CR + PR)/total × 100 %
cCalculated using Clopper Pearson method
dIncluding 17 patients with PR and 2 patients with unconfirmed PR
Fig. 2 Kaplan-Meier survival estimates for PFS—full analysis set. Median PFS for the monotherapy and combined therapy groups was
5.40 months (95 % CI 2.90, 9.80) and 7.90 months (95 % CI 6.10, 9.80), respectively
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abnormalities or changes from baseline were not observed
in ECG, urinalysis, ECOG performance status, body
weight, or other vital signs for study subjects during the
course of the study treatments.
Discussion
In the treatment of metastatic breast cancer, tumor re-
sistance to the standard chemotherapy or adjuvant
chemotherapy with anthracyclines and taxanes remains
an area of substantial unmet medical needs.
The antineoplastic activities of epothilones have been
well characterized in vitro and in vivo and further estab-
lished by the FDA approval of the epothilone analog,
ixabepilone [1–4, 7, 8]. In clinical trials, ixabepilone has
demonstrated efficacy in the treatment of metastatic and
locally advanced breast cancer in patients who had gone
through multiple courses of standard chemotherapies and
had failed or suffered recurrence [4, 9–11]. However, the
toxicities related to ixabepilone treatment, such as neutro-
penia (grade 3, 31 %; grade 4, 23 %), sensory neuropathy
(PN, grade 3, 13 %; grade 4, 1 %), and fatigue (grade 3,
13 %; grade 4, 1 %) were very prominent and often re-
sulted in discontinuation of the treatment.
Utidelone is an epothilone analog produced by genetic-
ally engineered S. cellulosum using enhanced production
and fermentation technology [6]. The active ingredient is
isolated and purified directly from the fermentation of the
engineered production strain without further chemical
synthesis or modification. Thus, the highly purified utide-
lone can be manufactured with well-controlled quality and
scalable production capacity. This process leads to high
yields and a low cost of utidelone, in contrast to the
first FDA-approved epothilone drug ixabepilone, which
needs several steps of chemical synthesis after bacterial
Table 4 Study subject adverse events (AEs) by severity
AEsa Number (%) patients
Grade Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
Study Combination therapy: utidelone (30 mg/m2) + capecitabine
(2000 mg/m2) n = 33
Monotherapy utidelone (40 mg/m2)
n = 70
Event of grade 3 or above 19 (57.6) 13 (18.6)
Hematologic toxicity 7 (24.2) 5 (15.2) 2 (6.1) 8(11.4) 9 (12.9) 5 (7.1)
Neutrophil decreased 2 (6.1) 2 (6.1) 2 (6.1) 11(15.7) 3(4.3) 5 (7.1)
WBC decreased 5 (15.2) 6 (18.2) 0 6 (8.6) 9 (12.9) 1(1.4)
Hemoglobin decreased 1 (3.0) 0 0 1 (1.4) 2(2.9) 0
Platelet decreased 0 2 (6.1) 0 2 (2.9) 0 0
Hepatic and renal function abnormalities 2 (6.1) 1 (3.0) 0 8 (8.6) 3 (4.3) 0
GGT increased 0 0 0 1 (1.4) 1 (1.4) 0
ALT increased 1 (3.0) 0 0 7 (10) 2( 2.9) 0
AST increased 1 (3.0) 0 0 4 (5.7) 2 (2.9) 0
Total bilirubin increased 1 (3.0) 1 (3.0) 0 3 (4.3) 0 0
Gastrointestinal toxicity 10 (30.3) 17 (51.5) 0 28 (40) 10 (14.3) 2 (2.9)
Decreased appetite 19 (57.6) 0 0 14 (20) 1 (2.9) 0
Diarrhea 8 (24.2) 2 (6.1) 0 9 (12.9) 5 (7.1) 2 (2.9)
Vomiting 4 (12.2) 10 (30.3) 0 6 (8.6) 1 (1.4) 0
Nausea 10 (30.3) 16 (48.5) 0 22 (31.4) 2 (2.9) 0
Neurological toxicity 2 (12.2) 13 (39.4) 17 (51.5) 28 (40) 23 (32.9) 7 (10)
Peripheral neuropathy 4 (12.2) 13 (39.4) 15 (45.5) 26 (37.1) 23 (32.9) 6 (8.6)
Insomnia 10 (30.3) 0 1 (3.0) 5 (7.1) 0 0
Dizziness 17 (51.5) 1 (3.0) 2 (6.1) 7 (10) 4 (5.7) 2 (2.9)
Hand-foot syndrome 7 (21.2) 1 (3.0) 5 (15.2) 1 (1.4) 0 0
Other
Myalgia and arthralgia 5 (15.2) 15 (45.5) 5 (15.2) 9 (12.9) 1 (1.4) 1 (1.4)
Alopecia 2 (6.1) 4 (12.2) 1 (3.0) 20 (28.6) 4 (5.7) 1 (1.4)
Fatigue 13 (39.4) 6 (18.2) 1 (3.0) 8 (11.4) 9 (12.9) 5 (7.1)
aAEs according to Common Terminology Criteria for Adverse Events version 3.0
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fermentation and had higher cost. The high incidence
of grade 3 and grade 4 toxicities, together with the high
cost of ixabepilone, had greatly hindered the clinical
use of this drug.
This report of two open-label studies of utidelone in
metastatic breast cancer patients refractory to anthracy-
clines and/or taxanes, demonstrated a favorable efficacy
result, with once daily for 5-day dose regimen instead of
the standard q3w treatment. The combination therapy
study showed an ORR of 42.4 %, a median PFS of
7.9 months, and a median duration of response of
7.8 months. On the other hand, the utidelone monother-
apy study resulted in a 28.57 % ORR, a 5.4-month median
PFS, and a 7.3-month median duration of response. By
Jan. 2016, 18 patients had died in the combination study
arm and 14 patients still survived; the preliminary median
overall survival (OS) was 30.6 months. In the monother-
apy arm, 33 of the 70 patients had died, 27 patients still
survived, and 10 were lost to follow-up; the preliminary
median OS was 21.2 months. These preliminary data sug-
gested that utidelone may also significantly increase the
OS either used as a single agent or in combination with
capecitabine. However, the final OS still needs follow-up
and remains to be determined. In comparison, the phase
III combination therapy trial of ixabepilone plus capecit-
abine in metastatic and locally advanced breast cancer
patients resulted in a 34.7 % ORR, a 5.7-month median
PFS, and a 6.4-month median duration of response [4].
However, ixabepilone plus capecitabine did not im-
prove OS even for the patients who received two or
fewer prior chemotherapy regimens [12] and less pre-
treated than the patients enrolled in our study. The
phase II ixabepilone monotherapy trial study in pa-
tients with taxane-resistant MBC reported a 12 % ORR,
a 2.2-month median PFS, and a 10.4-month median
duration of response [13]. Although the current utide-
lone studies had smaller sample sizes than the reported
ixabepilone studies, our findings suggest that utidelone
may have efficacy more favorable to that of ixabepilone,
including ORR, PFS, and possibly also OS. These results
also indicated that utidelone could overcome resistance to
anthracyclines and taxanes, providing a novel therapeutic
option to fight against multidrug-resistant breast cancer.
The mechanisms underlying utidelone to overcome drug
resistance are yet to be investigated. It had been reported
previously that epothilone was not a substrate for p-
glycoprotein, also known as multidrug-resistant protein 1
(MDR1), or breast cancer resistance protein, also known
as BCRP/ABCG2 [14, 15].That may confer an advantage
to this investigational drug to bypass the mechanisms of
drug resistance. Utidelone may also gain the ability to
overcome drug resistance via other mechanisms. In this
regard, it had been reported that epothilones could in-
hibit the functions of actin cytoskeleton and its critical
regulator Rac1 GTPase [16], which are important players
in multidrug resistance [17–19].
In both combination and monotherapy studies, the
utidelone treatment-related toxicities were generally
mild to moderate and considered clinically manageable.
The major AEs associated with administration of utide-
lone alone or in combination with capecitabine were PN,
myalgia, and arthralgia. Of these associated AEs, even
though PN was considered to be the most problematic, it
could be managed with dose delay, dose reduction, or
treatment discontinuation, generally resulting in recovery
within 14–18 days for grade 3 PN. There were no deaths
attributed to utidelone administration during both studies.
Overall, utidelone was considered well tolerated in these
phase II trials.
In comparison with published data of other chemo-
therapies with similar mechanism of action, especially
with ixabepilone, utidelone showed some unique and
important features in terms of safety profile. One sur-
prise to the researchers was that the incidences of neu-
tropenia and other hematological toxicities were much
less prominent, suggesting that utidelone has quite mild
effect on myelosuppression, in contrast to paclitaxel, and
ixabepilone which in combination with capecitabine, as
high as 70 % of patients had grade 3/grade 4 neutropenia.
It seemed that the PN effect of utidelone, although prom-
inent, may also not so severe as ixabepilone considering
the incidence of grade 3/grade4 events, which was less
with much shorter recovery time to grade 1 or baseline
under our study conditions than that of ixabepilone [4]. In
addition, utidelone did not appear to have clinical signifi-
cant effects on hepatic and renal functions. Moreover, the
gastrointestinal toxic effect of utidelone seemed to be very
mild, since diarrhea and vomiting was not observed fre-
quently, but some other epothilone analogs, such as
epothilone B, caused severe gastrointestinal toxicities
[20]. Although the mechanism underlying these differ-
ences in toxic effects is yet to be elucidated, these
unique safety features represent important advantages
of utidelone.
Conclusions
In conclusion, utidelone demonstrated clear efficacy with
significant PFS improvement, good tolerability, and
manageable adverse events with an advantageous tox-
icity profile. This study strongly supports that utidelone
is a promising novel investigational drug as a single agent
and in combination with capecitabine as well for the treat-
ment of patients with advanced metastatic breast cancer
who had failed multiple courses of chemotherapy including
anthracyclines and taxanes or suffered recurrence. Utide-
lone could also offer an important therapeutic option in the
armamentarium of cancer treatment, especially for cancers
that are multidrug resistant.
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